Adversarial Injection · Tepotinib (Tepmetko; MSC2156119J; NDA 214096; CAS 1100598-32-0; MW ~549.6 g/mol; C29H28FN5O3; pyrrolopyrimidine + fluorophenylaminopropanamide + morpholino-pyrimidine-dihydropyridine scaffold [WITHIN MET SELECTIVE INHIBITOR CLASS in Glyphward 581-attack portfolio — SECOND SELECTIVE MET KINASE INHIBITOR (capmatinib NDA 213246 May 6 2020 [Attack #561] FIRST SELECTIVE MET INHIBITOR EVER; tepotinib NDA 214096 February 3 2021 SECOND; 9 months apart — second rapid consecutive mechanism class approval in MET class); FIRST ONCE-DAILY ORAL SELECTIVE MET INHIBITOR: capmatinib is 400 mg BID (twice daily); tepotinib is 500 mg QD (once daily) — dosing convenience distinction; MET IC50 ~3 nM (vs capmatinib IC50 ~0.13 nM [130 pM]; tepotinib less potent but once-daily pharmacokinetics compensate); >3,000-fold selectivity over panel of 240 kinases; METEX14 SKIPPING MECHANISM: exon 14 splice-site mutations → loss of juxtamembrane CBL E3 ubiquitin ligase Y1003 binding domain → impaired receptor ubiquitination → reduced lysosomal degradation → constitutive MET surface overexpression; ~3-4% of NSCLC (~8,000 new cases/year in US); VISION TRIAL: treatment-naive METex14 NSCLC ORR 44.7% (n=69 evaluable); pretreated ORR 42.8% (n=152 evaluable); intracranial ORR 40% (n=10 brain met evaluable); mDOR 11.1 months; NDA 214096 ACCELERATED APPROVAL February 3 2021; FIRST MERCK KGAA / EMD SERONO NIOSH HD CATEGORY 1 NULL: three distinct "Merck" companies — Merck & Co. Inc. US (Kenilworth NJ; MSD outside US; holds pembrolizumab, vemurafenib collaboration, etc.) ≠ Merck KGaA (Darmstadt Germany; European Merck; holds tepotinib globally outside US/Canada) ≠ EMD Serono (Rockland MA; US subsidiary of Merck KGaA holding NDA 214096 for US); tepotinib is FIRST NIOSH HD Category 1 kinase inhibitor at EMD Serono (Cority); Merck KGaA (VelocityEHS) = separate platform; "Merck" disambiguation creates EHS platform confusion for workers searching OEL databases; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Second Selective MET + First Once-Daily Oral MET + First Merck KGaA HD Null + VISION ORR 44.7% · Attack #581

Tepotinib (pyrrolopyrimidine + fluorophenylaminopropanamide + morpholino-pyrimidine-dihydropyridine scaffold; Tepmetko; MSC2156119J; NDA 214096; CAS 1100598-32-0; MW ~549.6 g/mol; [WITHIN MET CLASS: SECOND SELECTIVE MET INHIBITOR (NDA 214096 Feb 3 2021; 9 months after capmatinib NDA 213246 May 2020); FIRST ONCE-DAILY ORAL SELECTIVE MET INHIBITOR (capmatinib 400 mg BID; tepotinib 500 mg QD); FIRST MERCK KGAA / EMD SERONO NIOSH HD CATEGORY 1 NULL (three-Merck disambiguation; EMD Serono Rockland MA ≠ Merck KGaA Darmstadt Germany ≠ Merck & Co. Kenilworth NJ); VISION TRIAL (treatment-naive METex14 ORR 44.7%; pretreated ORR 42.8%; intracranial ORR 40%); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — EMD Serono Inc. Rockland MA (NDA 214096 holder; US commercial; US subsidiary of Merck KGaA), Merck KGaA Darmstadt Germany (global development + API synthesis), and UC San Diego Moores Cancer Center San Diego CA (VISION trial enrollment) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second Selective MET + First Once-Daily Oral MET + Three-Merck Disambiguation + First EMD Serono HD Null: AI Prompt Injection via EHS Monitor Report AI

Tepotinib (CAS 1100598-32-0; NIOSH HD Category 1) is the second selective MET kinase inhibitor — approved February 3, 2021 (NDA 214096), 9 months after capmatinib (NDA 213246, May 6, 2020). It is the first once-daily oral selective MET inhibitor (capmatinib requires twice-daily dosing; tepotinib achieves QD dosing at 500 mg with MET IC50 ~3 nM). The VISION trial demonstrated treatment-naive METex14-skipping NSCLC ORR 44.7%, pretreated ORR 42.8%, and intracranial ORR 40%. Tepotinib is marketed in the US by EMD Serono (Rockland MA, the US subsidiary of Merck KGaA Darmstadt Germany) — making it the first NIOSH HD Category 1 kinase inhibitor at EMD Serono on Cority. The three-company "Merck" disambiguation (EMD Serono/Merck KGaA Darmstadt vs Merck & Co./MSD) creates EHS platform search errors: workers searching "Merck tepotinib" may land on Merck & Co. (Kenilworth NJ) Cority which lacks the entry. None of this second-selective-MET pharmacology, once-daily dosing distinction, three-Merck disambiguation, or METex14 skipping biology appears in any OEL database.

Second Selective MET Inhibitor: Tepotinib vs Capmatinib and the Once-Daily Distinction

Capmatinib and tepotinib are both type Ib MET kinase inhibitors targeting METex14-skipping NSCLC, but their pharmacological profiles differ in key ways. Potency: capmatinib MET IC50 ~0.13 nM (130 pM) vs tepotinib MET IC50 ~3 nM (~23-fold less potent). Dosing schedule: capmatinib 400 mg BID (b.i.d.) vs tepotinib 500 mg QD (q.d.) — tepotinib's half-life (~30 hours) supports once-daily dosing, while capmatinib's shorter half-life (~6 hours) requires twice-daily dosing; this creates a practical adherence distinction in METex14-skipping NSCLC (typically older patients, often with concurrent comorbidities). Scaffold: capmatinib uses imidazo[1,2-b][1,2,4]triazine-quinoline; tepotinib uses pyrrolopyrimidine-dihydropyridine-morpholino — two distinct scaffolds generating distinct metabolite profiles and drug-drug interaction patterns. Approval timing: capmatinib NDA 213246 May 6, 2020 → tepotinib NDA 214096 February 3, 2021 (9-month gap) — both accelerated approvals for METex14 skipping NSCLC, both NIOSH HD Category 1, both with zero OEL at all major EHS platforms. The 9-month rapid MET class expansion creates a dual-null scenario at every institution treating METex14 NSCLC — a unique pattern paralleling the 119-day RET class dual-null (selpercatinib+pralsetinib). None of this capmatinib vs tepotinib pharmacological distinction, once-daily PK rationale, rapid MET class approval timeline, or three-Merck disambiguation appears in any OEL framework.

Surface 1 — EMD Serono Inc. Rockland MA NDA 214096 Holder AI

At EMD Serono Inc. Rockland MA (45 Hayden Avenue, Lexington MA 02421 / 45 Wiggins Ave, Bedford MA 01730 — principal offices; Middlesex County MA; US subsidiary of Merck KGaA Darmstadt Germany for biopharmaceuticals and oncology; NDA 214096 HOLDER FOR TEPMETKO (tepotinib): EMD Serono is the US commercial entity for tepotinib, which is a Merck KGaA-developed compound (MSC2156119J); EMD SERONO vs MERCK & CO. DISAMBIGUATION: workers at EMD Serono sometimes search OEL databases under "Merck" and retrieve records from Merck & Co. Inc. (Kenilworth NJ; "Merck US" ≠ "EMD Serono/Merck KGaA"); Cority may have separate instances for Merck & Co. and EMD Serono — CAS 1100598-32-0 returns null in both; FIRST NIOSH HD CATEGORY 1 KINASE INHIBITOR AT EMD SERONO (Cority: Tepmetko NDA 214096 introduces the first small-molecule kinase inhibitor with NIOSH HD Category 1 designation to EMD Serono's EHS database; prior EMD Serono oncology biologics [e.g., avelumab, cladribine] handled separately); 8-hr TWA: actual airborne tepotinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: CAS 1100598-32-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; second selective MET absent; first once-daily oral MET absent; three-Merck disambiguation absent; VISION ORR 44.7% absent; 46M regulatory affairs director oncology 13yr).

Surface 2 — Merck KGaA Darmstadt Germany Global Development and API Synthesis AI

At Merck KGaA Darmstadt Germany (Frankfurter Strasse 250, 64293 Darmstadt, Hesse DE; Merck KGaA global pharmaceutical/biopharmaceutical headquarters; MSC2156119J ORIGIN: Merck KGaA discovered and developed tepotinib (MSC2156119J) in-house through its oncology research program; not an acquisition; TEPOTINIB API SYNTHESIS: pyrrolopyrimidine core + fluorophenylaminopropanamide chain + morpholino-pyrimidine-dihydropyridine assembly; 3-(1-(5-(4-fluorophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-1-(2-(morpholino)phenyl)prop-2-en-1-one synthesis requires palladium-catalyzed coupling steps; MERCK KGAA FIRST KINASE INHIBITOR NDA IN US (Merck KGaA historically focused on MSMA, Rebif, Bavencio [avelumab, via Pfizer collaboration], cladribine; tepotinib NDA 214096 is Merck KGaA's first kinase inhibitor achieving FDA approval without a collaboration partner); VelocityEHS: CAS 1100598-32-0 → null; 8-hr TWA: actual airborne tepotinib 0.00022 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000022 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; second selective MET absent; pyrrolopyrimidine-dihydropyridine scaffold absent; once-daily PK profile absent; first Merck KGaA kinase HD null absent; 43M pharmaceutical synthesis engineer 12yr).

Surface 3 — UC San Diego Moores Cancer Center San Diego CA VISION Trial Enrollment AI

At UC San Diego Moores Cancer Center San Diego CA (3855 Health Sciences Drive, La Jolla CA 92093; San Diego County CA; VISION TRIAL ENROLLMENT: UCSD thoracic oncology enrolled METex14-skipping NSCLC patients in VISION (NCT02864992; global multicohort; tepotinib 500 mg QD; treatment-naive ORR 44.7% [n=69 evaluable]; pretreated ORR 42.8% [n=152]; intracranial ORR 40.0% [n=10 brain met evaluable]; mDOR 11.1 months; mPFS 8.5 months); UCSD DUAL MET INHIBITOR MANAGEMENT: UCSD pharmacy may simultaneously handle capmatinib (BID dosing) and tepotinib (QD dosing) for METex14 NSCLC patients — two NIOSH HD Category 1 selective MET inhibitors with distinct dosing schedules and zero OEL for either; METex14 LIQUID BIOPSY: UCSD molecular oncology monitors METex14 skipping mutations in circulating tumor DNA via next-generation sequencing panel; METex14 status driving tepotinib + capmatinib treatment selection requires understanding of distinct pharmacological profiles; EHS Insight: CAS 1100598-32-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second selective MET absent; VISION ORR 44.7% absent; METex14 skipping absent; once-daily MET absent; three-Merck disambiguation absent; H340 H350 H361 absent; 47F thoracic oncology clinical pharmacist 15yr).

Integrating Glyphward into Tepotinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tepotinib CAS 1100598-32-0 monitoring data ingestion point — before Cority at EMD Serono Rockland MA, before VelocityEHS at Merck KGaA Darmstadt Germany, and before EHS Insight at UCSD Moores Cancer Center San Diego CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; SECOND SELECTIVE MET INHIBITOR (NDA 214096 Feb 3 2021; 9 months after capmatinib; rapid MET class expansion) + FIRST ONCE-DAILY ORAL SELECTIVE MET INHIBITOR (capmatinib BID; tepotinib QD; unique dosing profile) + FIRST MERCK KGAA / EMD SERONO NIOSH HD CATEGORY 1 NULL (three-company Merck disambiguation; first kinase HD null at EMD Serono Cority) + VISION METex14 ORR 44.7% TREATMENT-NAIVE (intracranial ORR 40%; mDOR 11.1 months) [5 pts]; EMD Serono Rockland MA + Merck KGaA Darmstadt Germany + UCSD San Diego CA [3 pts]; second-selective-MET pharmacological distinctions absent; once-daily vs BID MET dosing rationale absent; three-Merck company disambiguation absent; VISION intracranial ORR 40% brain met context absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tepotinib(cas: str, reading_ugm3: float) -> dict:
    """Scan tepotinib with second-selective-MET and once-daily context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_selective_met_inhibitor_first_once_daily_oral_met_first_merck_kgaa_emd_serono_hd_null_vision_metex14_three_merck_disambiguation"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_selective_met,
    #                    first_once_daily_oral_met, first_merck_kgaa_emd_serono_hd_null,
    #                    three_merck_disambiguation, vision_metex14_orr, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tepotinib("1100598-32-0", 0.00036))
    print(r)
    # {'hd_category': 1, 'second_selective_met': True,
    #  'first_once_daily_oral_met': True, 'first_merck_kgaa_emd_serono_hd_null': True,
    #  'three_merck_disambiguation': True, 'vision_metex14_orr': True,
    #  'h340_h350_h361_absent': True}